Chemical Synthesis of All Phosphatidylinositol Mannoside (PIM) Glycans from Mycobacterium tuberculosis has been claimed in a patent application filed by Seeberger, Peter H. et al.[1] Phosphatidylinositol mannosides (PIMs) are biol. important glycoconjugates and represent common essential precursors of more complex mycobacterial cell wall glycolipids including lipomannan (LM), lipoarabinomannan (LAM), and mannan capped lipoarabinomannan (ManLAM). Synthetic PIMs constitute important biochem. tools to elucidate the biosynthesis of this class of mols., to reveal PIM interactions with host cells, and to investigate the function of PIMs as potential antigens and/or adjuvant for vaccine development.
A method for screening in vitro drug candidates for the treatment of tuberculosis by interfering with the arabinogalactan biosynthesis has been disclosed in a patent application[2] filed by UNIV. PAVIA [IT]. The drugs obtainable through the screening method of the invention are selected among monoclonal antibodies against Rv3790 protein and mRNA antisense sequences for rv3790 gene.
UAB RESEARCH FOUNDATION [US] has filed a patent application US2011160123 [TARGETING THE EFFLUX SYSTEMS OF MYCOBACTERIUM TUBERCULOSIS] wherein a method is provided for reducing drug resistance in a Mycobacterium tuberculosis (Mtb), said method comprising contacting the Mtb with an agent which inhibits the activity of an efflux complex. The efflux complex comprises an efflux channel (Rv1698, TolC-like efflux channel) and an efflux pump (Rv0194). The efflux channel inhibitor or blocker comprises Ru(II)quaterpyridinium complex or a derivative thereof. The patent application claims a method of treating Mycobacterium tuberculosis (Mtb) in a subject, said method comprising: (a) administering to the subject an agent that inhibits the activity of an efflux complex; and (b) administering to the subject a tuberculosis treating agent.
Key Words: multidrug resistant tuberculosis, extensively drug resistant tuberculosis, multidrug resistant TB, extensively drug resistant TB, MDR TB, XDR TB, mycobacterium tuberculosis, mycobacterial infection, literature, research, publications, patents.
UAB RESEARCH FOUNDATION [US] has filed a patent application US2011160123 [TARGETING THE EFFLUX SYSTEMS OF MYCOBACTERIUM TUBERCULOSIS] wherein a method is provided for reducing drug resistance in a Mycobacterium tuberculosis (Mtb), said method comprising contacting the Mtb with an agent which inhibits the activity of an efflux complex. The efflux complex comprises an efflux channel (Rv1698, TolC-like efflux channel) and an efflux pump (Rv0194). The efflux channel inhibitor or blocker comprises Ru(II)quaterpyridinium complex or a derivative thereof. The patent application claims a method of treating Mycobacterium tuberculosis (Mtb) in a subject, said method comprising: (a) administering to the subject an agent that inhibits the activity of an efflux complex; and (b) administering to the subject a tuberculosis treating agent.
Key Words: multidrug resistant tuberculosis, extensively drug resistant tuberculosis, multidrug resistant TB, extensively drug resistant TB, MDR TB, XDR TB, mycobacterium tuberculosis, mycobacterial infection, literature, research, publications, patents.
No comments:
Post a Comment